Search Results

GigaGen Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of its anti-CTLA-4 oncology drug, GIGA-564, for the treatment of metastatic or locally advanced solid tumors.

GigaGen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase 1 trial to evaluate the company’s oncology candidate, GIGA-564, for the treatment of solid tumors.

GigaGen Inc. a subsidiary of Grifols, announced the company has been granted an expansion of its contract with the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to develop synthetic human antibody treatments for botulinum neurotoxins.

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced that it has signed an agreement with the National Cancer Institute, part of the National Institutes of Health, to advance development of the company’s differentiated anti-CTLA-4 antibody drug candidate for cancer treatment, GIGA-564.

GigaGen Inc. presented investigational new drug (IND)-enabling data and the clinical trial design for its first-in-human Phase 1 study evaluating the company’s oncology candidate, GIGA-564, at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed a license agreement with Dutch biotech ProteoNic B.V. for the use of its premium 2G UnicTM technology platform to enable high-yield production of GigaGen’s mono- and polyclonal antibody drug candidates.

GigaGen Inc. announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombinant human polyclonal antibody discovery platform against biological threats of interest to the DOD.